Subsequent Events

3 Months Ended

Oct. 31, 2013

Subsequent Events [Abstract]

Subsequent Events

8. Subsequent Events

On December 3, 2013, Lightlake announced that the initial findings of its clinical trial with the National Institute on Drug Abuse ("NIDA"), part of the National Institutes of Health, supports Lightlake's intranasal delivery of naloxone as a promising innovative treatment for reversing opioid overdoses. Initial data from the study shows that the Company's naloxone nasal spray potentially can be delivered into the blood stream at least as quickly as the injection process currently used by hospitals, first responders, and others treating opioid overdoses. Naloxone is a medicine currently available through injection that can rapidly reverse the overdose of prescription and illicit opioids. The Company, in partnership with NIDA, had commenced this two-week clinical trial on September 23rd, 2013.